To experimentally determine whether the CRC cell states are functionally linked to MAPK activity, we blocked MAPK signaling in CRC organoids by the MEK1/2 inhibitor Selumetinib (AZD6244) or by Selumetinib in combination with the EGFR inhibitor Sapatinib (AZD8931) and analyzed singe‐cell gene expression after 48 h (Fig 4D). The gene discussed is MAP2K1; the disease is colorectal carcinoma.